Cel Sci (CVM) Total Liabilities (2010 - 2026)
Cel Sci (CVM) posted Total Liabilities of $10.8 million for Q1 2026, down 7.85% sequentially from $11.8 million in Q4 2025, and down 21.56% YoY from $13.8 million in Q1 2025.
Cel Sci (CVM) Total Liabilities (2010 - 2026) Analysis & Trends
Cel Sci has reported Total Liabilities for 16 years, with the latest figure at $10.8 million in Q1 2026.
- Quarterly Total Liabilities fell 21.56% year-over-year to $10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.8 million (down 21.56% YoY) and the FY2025 annual result came in at $12.2 million, down 13.64% from the prior year.
- Total Liabilities eased to $10.8 million in Q1 2026 per CVM's latest filing, from $11.8 million in the prior quarter.
- Over five years, Total Liabilities peaked at $19.0 million in Q1 2022 and troughed at $10.8 million in Q1 2026.
- A 5-year average of $15.5 million and a median of $15.7 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities fell 0.0% in 2022, then retreated 21.56% in 2026.
- Over 5 years, Total Liabilities stood at $18.0 million in 2022, then fell by 10.61% to $16.1 million in 2023, then dropped by 10.4% to $14.4 million in 2024, then fell by 18.31% to $11.8 million in 2025, then retreated by 7.85% to $10.8 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $10.8 million, $11.8 million, and $12.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 10.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.83 Mn |
| Dec 31, 2025 | 11.76 Mn |
| Sep 30, 2025 | 12.20 Mn |
| Jun 30, 2025 | 13.31 Mn |
| Mar 31, 2025 | 13.81 Mn |
| Dec 31, 2024 | 14.39 Mn |
| Sep 30, 2024 | 14.12 Mn |
| Jun 30, 2024 | 15.60 Mn |
| Mar 31, 2024 | 15.74 Mn |
| Dec 31, 2023 | 16.06 Mn |
| Sep 30, 2023 | 17.31 Mn |
| Jun 30, 2023 | 17.53 Mn |
| Mar 31, 2023 | 18.05 Mn |
| Dec 31, 2022 | 17.97 Mn |
| Sep 30, 2022 | 18.36 Mn |
| Jun 30, 2022 | 18.16 Mn |
| Mar 31, 2022 | 19.03 Mn |
| Dec 31, 2021 | 18.32 Mn |
| Sep 30, 2021 | 19.34 Mn |
| Jun 30, 2021 | 19.85 Mn |